S&P 500 Rejects.

Stocks that got rejected from S&P 500 in 2024 | S&P 500 rejects

BIO

Bio-Rad Laboratories, Inc. is a U.S.-based developer and manufacturer of specialized technological products for the life science research and clinical diagnostic markets. Here is a summary of the company based on the provided Yahoo Finance profile:

Company Profile Summary:

Removal from S&P 500 in 2024:

As of my last update (prior to the query date of October 30, 2024), specific reasons for Bio-Rad Laboratories' removal from the S&P 500 index in 2024 are not directly available in the provided query results. Index changes like these are typically due to one or more of the following reasons, though the exact motivation would need to be confirmed through S&P Dow Jones Indices' official communications or news releases:

  • Market Capitalization:** Significant reduction in market cap below S&P 500 thresholds.
  • Merger/Acquisition:** If Bio-Rad was involved in a merger or acquisition that altered its standing or eligibility.
  • Industry Representation:** Adjustment in the index's sector balance, where another company better represented the life sciences sector.
  • Financial Performance:** Prolonged underperformance against S&P 500 index criteria for financial health and stability.
  • Eligibility Criteria Changes:** Updates in the S&P 500's eligibility criteria that Bio-Rad no longer meets.

Disclaimer:** The reasons for Bio-Rad Laboratories' removal from the S&P 500 in 2024 are speculative based on common practices and were not explicitly stated in the provided resources. For the most accurate and up-to-date information, please refer to official announcements from S&P Dow Jones Indices or Bio-Rad Laboratories.


Rejects and Newcomers:


Rejects and Newcomers: